PQ Pharmacy LLC, Brooksville, FL

Is PQ Pharmacy LLC an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names PQ Pharmacy LLC in Brooksville, FL, first registered Oct 29, 2020 and most recently registered Dec 11, 2025. FDA lists its last inspection as Jun 1, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
Brooksville, FL
Initial registration
Oct 29, 2020
Most recent registration
Dec 11, 2025
Last inspection
Jun 1, 2026
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Open
Intends to compound sterile drugs from bulk substances
Yes
Earlier inspections
FDA notes that an earlier inspection led to a Form 483, warning letter or other action

FDA inspections and actions on record

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as PQ Pharmacy, LLC, Brooksville, FL, a 503B facility, with 6 listed actions, including 4 Form 483s and 1 warning letter (2022 to 2026).

Document
Jun 1, 2026Form 483483 Issued 06/01/2026fda.gov
Oct 10, 2025Warning letterWarning Letter (10/10/2025)fda.gov
Apr 4, 2025Form 483483 issued 04/04/2025fda.gov
Mar 30, 2023FMD-145 letterFMD-145 Letter Issued 3/30/2023Not linked by FDA
Nov 17, 2022Amended Form 483Amended 483 Issued 11/17/2022FDA copy (archived)
Oct 27, 2022Form 483483 Issued 10/27/2022fda.gov

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists PQ Pharmacy LLC, Brooksville, FL (FEI number 3017374013), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Apr 4, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30173740131266008
Oct 27, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30173740131182140

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 25 numbered observations in all, across 4 inspections ending Oct 27, 2022 to Jun 1, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Apr 20, 2026 to Jun 1, 2026: 7 observations

Firm on the cover
PQ Pharmacy LLC, 15215 Technology Dr, Brooksville, FL 34604-0690
FEI number
3017374013
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Specifically,

Media Fills

A) Your facility failed to follow written procedure S601002, entitled "Validation of Aseptic Processes by Simulation (Media Fill)" version 12 dated 12/02/2025 that requires you to revalidate the media fill process with <Redacted B4> runs if you obtain a turbid unit. On 06/16/2025, a media fill out of specification (OOS) occurred for lot <Redacted B4> during dropper bottle operations recovering one (1) turbid unit. Your response to this OOS was limited to decertifying the individual suspected of causing the contamination. You did not assess the aseptic integrity of the manufacturing process itself or evaluate its impact on the products you manufacture.

B) Your media fill process is deficient as you have not ensured interventions required by the protocol are comprehensive and are simulated by all operators. Additionally, you use <Redacted B4> vials to simulate your <Redacted B4> vialing process. You have not evaluated whether turbidity can be adequately detected in these vials. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

Specifically, your firm has not established adequate procedures and controls for the maintenance, certification, and qualification of HEPA filters, laminar air flow hoods (LAFH), biological safety cabinets (BSC), and cleanroom HVAC systems used for sterile drug production. HVAC failures have recurred without effective corrective action and oversight by the quality unit. For example,

A) Your firm has not performed installation and operational qualification (10/OQ) for the HVAC systems and HEPA filtered air supply in the hazardous and non-hazardous ISO 7 and 8 cleanrooms, as confirmed by you, the CEO. Additionally, your firm has not established a written procedure governing routine qualification of your facility used in production of sterile drug products.

B) According to your Quality Manager, cleanroom, LAFH, and BSC qualification acceptance criteria were not formally established between your firm and your contractor. ...

Read the full 483 (PDF on fda.gov)

Observation 3

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

A) DEV2025047, initiated on 07/02/2025 in response to a turbid media fill unit from lot <Redacted B4> identified "operator error" as the root cause without evaluating potential impacts of other process inputs such as gowning, material sterility and handling, and environmental controls. Additionally, the root cause was attributed to an individual based on speculation, without an established process for tracing the timing of when units were filled/handled.

impacts of other process inputs such as gowning, material sterility and handling, and environmental controls. Additionally, the root cause was attributed to an individual based on speculation, w ithout an established process for tracing the timing of when units were fil led/handled.

B) DEV2025048 was initiated on 07/07/2025 in response to out-of-specification sterility results recovered from lot <Redacted B4>. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Records of the inspections of automatic, mechanical or electronic equipment, including computers or related systems are not maintained.

Specifically,

A) During post-use <Redacted B4> of the sterilizing <Redacted B4> used for prednisolone sodium phosphate 1% / moxifloxacin HCI 0.5% / bromfenac 0.09% PF, Lot PMB12152SCH BUD 12/15/2026, two (2) consecutive tests resulted in the error message " Error: <Redacted B4> Not Obtainable"; neither were recorded in the batch record, subjected to <Redacted B4> <Redacted B4> operations review, or reviewed by your quality unit.

review, or reviewed by your quality unit.

B) Procedure S403400, "Use and Maintenance of <Redacted B4> "Version 3, dated 12SEP2025, does not address "error" results and provides no instruction for their documentation, escalation, or investigation.

C) Quality Assurance does not periodically review audit trails or test results stored in the <Redacted B4> instrument. Your Quality Manager confirmed these reviews are not performed.

D) Procedure S403400, Section 7.9.23 indicate <Redacted B4> data can be backed up to external storage. However, your CEO confirmed that no backup is performed to prevent data loss.

Observation 5

The responsibilities and procedures applicable to the quality control unit are not in writing.

Specifically, you have not established a procedure to ensure critical data is reviewed and verified by a second person prior to batch release. For example,

A) Data generated from environmental monitoring (EM) plates post incubation are read by a <Redacted B4> <Readcted B4> and are not subject to a <Redacted B4> review. Observations interpreted from the original data (EM plates) are recorded on a form that is ultimately reviewed by the quality unit. Your quality unit has no process for reviewing the original data generated from the EM plates for accuracy.

Observation 6

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not written and followed.

Specifically,

Visual Inspection Operations

You have not ensured that operators conducting 100% <Redacted B4> visual inspection are capable of identifying all defined visible defects across your sterile drug product containers, including vials, syringes, and eye drop containers. This is evidenced by:

A) During the walk-through of your facility on 04/28/2026, we identified what appears to be bubbles in the plunger threads of syringe <Redacted B4> when reviewing the units used to qualify your visual inspection operators. Upon inquiry with your visual inspection operators, it was determined that this occurrence had neither been identified nor recognized as a potential defect type for the syringe product manufactured at your facility. The product manufactured in the syringe is Mitomycin lmg/ml 40ml. Syringe products, when distributed, are shipped via <Redacted B4>, which may involve transport.

the syringe is Mitomycin lmg/ml 40ml. Syringe products, when distributed, are shipped via I (6)(4) I, which may involvifiX'l transport. ...

Read the full 483 (PDF on fda.gov)

Observation 7

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that drug product containers conform to appropriate standards of identity, strength, quality and purity.

Specifically,

A) Your finished product testing used to release finished drug products for commercial distribution and perform stability testing does not include an evaluation of impurities and degradants.

B) You do not have a scientific rationale for not performing identity testing for glycerin and propylene glycol, which includes evaluating acceptable levels of diethylene glycol and ethylene glycol. These components used in part for the manufacture of sterile drug products.

Inspection Mar 25, 2025 to Apr 4, 2025: 4 observations

Firm on the cover
PQ Pharmacy LLC, 15215 Technology Dr, Brooksville, FL 34604 -0690
FEI number
3017374013
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Your fnm failed to establish adequate written procedures for production and process controls designed to assure that the diug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically,

11 a) Your firm failed to conduct hold time studies to justify the <Redacted B4> hold times for your bulk solution bag before dosing into final product containers for al products. While a media fill was performed to challenge the <Redacted B4> hold period, your firm has not assessed potential risks or the impact of extended hold times on the finished product and its shelf life. Batches that underwent hold times during processing were not included in stability studies. Additionally, no studies have been conducted to define the storage conditions, nor do they address the container closure system (packaging integrity), chemical stability, or sampling timepoints. For example, the following lots underwent hold times during processing and were released without scientific data to support the hold times:

Drug Name

Volume

Dosage Form

Lot Number

Bulk BagHold Time

ed B4>

Prednisolone Sodium Phosphate/Bromfenac1%/0.09% WITH BAK

Days ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.

Specifically

a) During production from March 25 to March 28, 2025, operators' gown sleeves, wrists, and hands were observed laying down in contact with the ISO-5 classified LFH/BSC work surface. Your aseptic operators <Redacted B4> along the inside surface of the ISO 5 hood during aseptic production of drug products. Furthermore, the sleeves <Redacted B4> making contact with the clean area. For example, on 3/28/2025, during dosing process for Semaglutide 5mg vials, lot <Redacted B4, I observed the aseptic operators hands, wrists, and gowning sleeves in contact with the ISO-5 work surface <Redacted B4>, As per procedure S600200, "Environmental Monitoring of Personnel, PEC, ana Supporting Areas," Revision No. 6, Effective 04/29/2024, personnel monitoring requires sampling from operator sleeves during production. Following the dosing of Prednisolone Sodium Phosphate/Moxifloxacin HCL/Bromfenac PF lot <Redacted B4> the personnel monitoring sample was taken at the of <Redacted B4> level of the gloves. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

a)

Your videos of smoke studies conducted on 09/23/2024 for PEC ID <Redacted B4> do not demonstrate the manipulations or conditions necessary to accurately represent the dynamic process used in the production of Semaglutide, Tirzepatide, Moxiflo:i;cacin HCL, and Phen7 hrine/Lidocaine. For example, Smoke Study 23SEP2024, PEC ID 61141 SIN <Redacted B4> 5mL Vial Crimping Dynamic, does not include the steps for aseptically capping and crimping vials during the dosing process.

b) Smoke Studies conducted in September 2024 appeal to exhibit turbulence in the Non-hazardous Cleanroom 1 ISO-7 area, the Laminai· Flow Hood PEC ID <Redacted B4> , and PEC ID <Redacted B4>. For example, Non-Hazardous Suite Smoke Study, September 2024, Cleanroom shows upward air flow between the 15:00 and 16:00 minute marks . Similarly, the Smoke Study 23SEP2024, PEC ID <Redacted B4> Static Smoke Study, shows upward turbulence in front of the PEC ID <Redacted B4> between 02:00 ana 2:30 minutes, with additional air turbulence inside the ISO-5 area at 4:43 minutes. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.

Specifically,

a ) Deviation report DEV2024072, initiated on 09/18/2024, was opened to investigate the presence of visible particulate identified during the bulk bag inspection. The defect was detected <Redacted B4>, prior to dosing stage of the sterilized <Redacted B4> 2L bulk solution containing Prednisolone Sodium Phosphate/Moxifloxacin HCV Bromfenac I %/0.5%/0.09% Ophthahnic Solution, Lot: <Redacted B4>. As a corrective action your firm <Redacted B4> the bulk solution bag and subsequently released the batch for distribution. However, the investigation was inadequate as it did not establish a definitive root cause for the presence of visible particulates following <Redacted B4>. Additionally, the investigation failed to assess potential <Redacted B4> concerns or identify the source of particulate containination, thereby limiting tlie implementation of effective corrective and preventive actions to mitigate recunence. ...

Read the full 483 (PDF on fda.gov)

Inspection Oct 11, 2022 to Oct 27, 2022: 7 observations

Firm on the cover
PQ Pharmacy LLC, 15215 Technology Dr, Brooksville, FL 34604 -0690
FEI number
3017374013
Establishment type on the cover
Outsourcing Facility (503B)
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The quality control unit lacks authority to review production records to assure that no errors have occurred and fully investigate errors that have occurred.

The quality control unit (QCU) did not fully investigate laboratory test results before releasing finished drug products.

Specifically,

A. Your firm did not have a validated test method for assay testing of your drug products, Prednisolone Sodium Phosphate/Moxifloxacin HCL/Bromfenac 1 %/0.5%/0.09% and Prednisolone Sodium Phosphate/Moxifloxacin HCL 1 %/0.5% ophthalmic solutions before release and distribution of final product. Lot l, <Redacted B4> assigned no beyond use date (BUD) was used for your <Redacted B4> test method validation for both ophthalmic solutions that was completed on <Redacted B4>. Prior to 10/27/2022, the following lots were distributed to customers with final assay results using an unvalidated test method:

• <Redacted B4> 8.6mL starting on 05/16/2022 <Redacted B4> units

• <Redacted B4> 5.6mL starting on 07/06/2022 <Redacted B4> units

• <Redacted B4> 5.6mL starting on 08/10/2022 <Redacted B4> units ...

Read the full 483 (PDF on fda.gov)

Observation 2

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically,

Your firm compounded Prednisolone Sodium Phosphate/Moxifloxacin HCL I %/0.5%/mL Ophthalmic Solution Lot number: <Redacted B4> on May 26, 2022, into <Redacted B4> bulk bag and held it for <Redacted B4> before filing into its finished form (droptainers) on June 8, 2022. Your firm's established hold time for this drug product is <Redacted B4>. This discrepancy was not identified by anyone including your quality unit and no investigation was performed. Additionally, operator <Redacted B4> who performed the manufacturing of this compound was only qualified for <Redacted B4> according to your media fill hold time study. This batch was released by your quality unit on July 01, 2022 for sale but was not distributed due to no client need before its product expiration date.

Laboratory Control System

Observation 3

An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.

Specifically, the beyond use date (BUD) for mitomycin (1mg/1ml) 40mg/40 ml in 50 ml syringe for bladder irrigation was changed < Redacte d B4> on <Redacted B4>, < Redacted B4>, <Redacted B 4>, on <Re dacted B4> and from <Redacted B4> for lot <Redacted B4> . This BUD was e xtended based on the stability bat ch contrac t lab test results for lot <Redacted B4>. This stability ba tch was not te sted using a con tract test l ab val idat ed test met hod for assa y until after the valid ati on of the test method which according to documentation occurred on <Redacted B4>.

Observation 4

The written stability program for drug products does not include reliable test methods.

Specifically, the stability batch <Redacted B4> was tested at the time points <Redacted B4> using an un-validated contract test lab test method for assay.

validated contract test lab test method for assay.

Facilities and Equipment System

Observation 5

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, the <Redacted B4> contact time listed in you SOP S110108 Deactivation, Decontamination, Cleaning, and Disinfection Program (DDCD) for Receiving, Storage, and Manufacturing Areas Sections 7.1.1.1 and 7.2.4 and SOP S302002 Facility Cleaning and Maintenance Section 7.1.5.4.1 was not in keeping with the <Redacted B4> manufacturer's recommended <Redacted B4> contact time.

lJ!~.ti±LJ

Food, Drug, and Cosmetic Act

Observation 6

Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.

Specifically, the following products were compounded during the reporting period 2022-1 according to your production log batch record, but were not identified on your report dated May 31, 2022 (2022-1 ):

1. Prednisolone Sodium Phosphate/ Moxifloxacin HCL/Bromfenac 1 %/0.5%/0.09% Ophth Solution produced March 3, 2022, in 5 mL volume was not reported for 2022-1

2. Prednisolone Sodium Phosphate/Moxifloxacin 1 %/0.05% Ophth Solution produced May 26, 2022, in 5 mL volume was not reported for 2022-1

3. Prednisolone Sodium Phosphate/Moxifloxacin 1 %/0.05% Ophth Solution produced May 26, 2022, in 8 mL volume was not reported for 2022-1.

Observation 7

Your outsourcing facility did not submit a report to FDA upon initial registration as an outsourcing facility identifying the drugs compounded during the previous six month period.

Specifically,

Your outsourcing facility did not submit a report to FDA identifying the drugs compounded or no products to report at the time of initial registration, October 29, 2020, and December 2020.

Inspection Oct 11, 2022 to Oct 27, 2022: 7 observations

Firm on the cover
PQ Pharmacy LLC, 15215 Technology Dr, Brooksville, FL 34604 -0690
FEI number
3017374013
Establishment type on the cover
Outsourcing Facility (503B)
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page
FDA document
Read the full 483 (Internet Archive copy FDA links)

Observation 1

The quality control unit lacks authority to review production records to assure that no errors have occurred and fully investigate errors that have occurred.

The quality control unit (QCU) did not fully investigate laboratory test results before releasing finished drug products.

Specifically,

A. Your firm did not have a validated test method for assay testing of your drug products, Prednisolone Sodium Phosphate/Moxifloxacin HCL/Bromfenac I %/0.5%/0.09% and Prednisolone Sodium Phosphate/Moxifloxacin HCL I %/0.5% ophthalmic solutions before release and distribution of final product. Lot PM0 41322SV PMB041322SV assigned no beyond use date (BUD) was used for your third-party test method validation for both ophthalmic solutions that was completed on I 0/2712022. Prior to I 0/27 /2022, the following lots were distributed to customers with final assay results using an unvalidated test method:

• PMB041922SV 8.6mL starting on 05/16/2022 <Redacted B4> units

• PMB060322SV 5.6mL starting on 07/06/2022 <Redacted B4> units

• PMB072522SV 5.6mL starting on 08/10/2022 <Redacted B4> units

AM ENDMENT 1

• PMB072722SV 8.6mL starting on 08/15/2022 <Redacted B4> units ...

Read the full 483 (Internet Archive copy FDA links)

Observation 2

The responsibilities and procedures applicable to the quality control unit are not fully followed.

AMENDM ENT 1

Specifically,

Your firm compounded Prednisolone Sodium Phosphate/Moxifloxacin HCL 1 %/0.5%/mL Ophthalmic Solution Lot number: PMO052622SV on May 26 2022, into a <Redacted B4> bulk bag and held it for 13 days before filling into its finished form <Redacted B4> on June 8, 2022. Your firm's established hold time for this drug product is <Redacted B4>. This discrepancy was not identified by anyone including your quality unit and no investigation was performed. Additionally, operator who performed the manufacturing of this compound was only qualified for 7 days according to your media fill hold time study. This batch was released by your quality unit on July 01, 2022 for sale but was not distributed due to no client need before its product expiration date.

Laboratory Control System

Observation 3

An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.

Specifically, the beyond use date (BUD) for mitomycin (1mg/1ml) <Redacted B4> in 50 ml syringe for bladder irrigation was changed from <Redacted B4> 60 days to 90 days on 5/4/2022, 90 days to 130 days on 7/8/2022 and from 130 to 180 days for lot This BUD was extended based on the stability batch contract lab test results for lot <Redacted B4> is stability batch was not tested using a contract test lab validated test method for assay until after the validation of the test method which according to documentation occurred on 4/26/2022.

Observation 4

The written stability program for drug products does not include reliable test methods.

AMENDMENT 1

validated contract test lab test method for assay.

Facilities and Equipment System

Observation 5

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, the <Redacted B4> contact time listed in you SOP S110108 Deactivation, Decontamination, Cleaning, and Disinfection Program (DDCD) for Receiving, Storage, and Manufacturing Areas Sections 7.1.1.1 and 7.2.4 and SOP S302002 Facility Cleaning and Maintenance Section 7.1.5.4.1 was not in keeping with the <Redacted B4>, manufacturer's recommendedŁ <Redacted B4> contact time.

Food, Drug, and Cosmetic Act

Observation 6

Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.

Specifically, the following products were compounded during the reporting period 2022-1 according to your production log batch record, but were not identified on your report dated May 31, 2022 (2022-1):

1. Prednisolone Sodium Phosphate/ Moxifloxacin HCL/Bromfenac 1 %/0.5%/0.09% Ophth Solution produced March 3, 2022, in 5 mL volume was not reported for 2022-1

2. Prednisolone Sodium Phosphate/Moxifloxacin 1 %/0.05% Ophth Solution produced May 26, 2022, in 5 mL volume was not reported for 2022-1

3. Prednisolone Sodium Phosphate/Moxifloxacin 1 %/0.05% Ophth Solution produced May 26, 2022, in 8 mL volume was not reported for 2022-1.

Observation 7

AMENDMENT 1

Your outsourcing facility did not submit a repo1t to FDA upon initial registration as an outsourcing facility identifying the drugs compounded during the previous six month period.

Specifically,

Your outsourcing facility did not submit a report to FDA identifying the drugs compounded or no products to report at the time of initial registration, October 29, 2020, and December 2020.

GLP-1 records in this index

The same legal name appears in 1 GLP-1 warning letter and 0 GLP-1 recall reports in this index. See the PQ Pharmacy, LLC record page.

Later letters FDA listsLetter
Oct 10, 2025Compounding Pharmacy/Adulterated Drug ProductsSemaglutideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

The PQ Pharmacy LLC pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 7 products naming liraglutide, semaglutide and tirzepatide under the labeler name “PQ Pharmacy LLC”, matched to this facility page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (7). The compounded product reports cover FDA reporting periods 2024-2 to 2025-2.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
81375-606LiraglutideLiraglutideINJECTIONSUBCUTANEOUS6 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2Compounded drugs
81375-614LiraglutideLiraglutideINJECTIONSUBCUTANEOUS15 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2Compounded drugs
81375-600SemaglutideSemaglutide 2.5mg/mLINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81375-601SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81375-605SemaglutideSemaglutide 5mg/mLINJECTION, SOLUTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81375-610TirzepatideTirzepatideINJECTION, SOLUTIONSUBCUTANEOUS10 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81375-620TirzepatideTirzepatideINJECTION, SOLUTIONSUBCUTANEOUS20 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.